New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsComparePEG-MGF vs Humanin

PEG-MGF vs Humanin

Side-by-side comparison of key properties, dosing, and research.

Anabolic & IGF
PEG-MGF
Anti-Aging & Longevity
Humanin
Summary
PEG-MGF (Pegylated Mechano Growth Factor) is a modified form of MGF (Mechano Growth Factor) where polyethylene glycol (PEG) chains have been attached to extend its half-life from minutes to days. Native MGF is released locally in muscle in response to mechanical stress and quickly degrades. PEGylation allows systemic administration with sustained circulation, enabling whole-body muscle repair and anabolic signaling rather than the purely local effect of native MGF.
Humanin is a mitochondria-derived peptide (MDP) encoded in the 16S rRNA region of the mitochondrial genome. It protects neurons and other cells from apoptosis, improves insulin sensitivity, and declines significantly with age. HNG (S14G-Humanin) is a synthetic analog with 1000x greater potency.
Half-Life
~3 days (due to PEGylation)
~4–8 hours (HNG)
Admin Route
SubQ
SubQ
Research
Typical Dose
200–400 mcg
2–8 mg
Frequency
2–3x per week
3–5 times per week
Key Benefits
  • Extended half-life (~3 days) vs native MGF (minutes)
  • Systemic muscle satellite cell activation via subcutaneous injection
  • Promotes muscle fiber repair and hypertrophy throughout the body
  • Enhanced recovery from intense training or muscle injury
  • Synergistic with IGF-1 LR3 and growth hormone peptides
  • Useful in sarcopenia, post-injury recovery, and athletic performance
  • Single injection provides multi-day anabolic signaling
  • Neuroprotection against amyloid-beta toxicity (Alzheimer's relevance)
  • Inhibits cellular apoptosis
  • Improves insulin sensitivity
  • Reduces cardiovascular risk markers
  • Anti-inflammatory effects
  • Correlates with longevity in centenarian studies
  • Protects against ischemic injury
  • Potential cancer cell apoptosis sensitization
Side Effects
  • Water retention and localized swelling
  • Potential hypoglycemia at high doses
  • Theoretical cancer growth risk (growth factor)
  • Injection site reactions
  • +1 more
  • Injection site irritation
  • Limited human safety data available
Stacks With